Verrica Pharmaceuticals (NASDAQ:VRCA) Announces Earnings Results, Misses Expectations By $0.12 EPS

Verrica Pharmaceuticals (NASDAQ:VRCA) released its quarterly earnings data on Monday. The company reported ($0.49) EPS for the quarter, missing the consensus estimate of ($0.37) by ($0.12), Zacks reports. Verrica Pharmaceuticals had a negative net margin of 625.06% and a negative return on equity of 3,102.90%. The business had revenue of ($1.78) million for the quarter, compared to the consensus estimate of $7.53 million.

Verrica Pharmaceuticals Price Performance

Shares of VRCA stock opened at $0.80 on Wednesday. The stock has a 50 day moving average price of $1.67 and a 200 day moving average price of $5.17. Verrica Pharmaceuticals has a 52-week low of $0.75 and a 52-week high of $11.41. The company has a debt-to-equity ratio of 29.58, a current ratio of 2.36 and a quick ratio of 2.23.

Analyst Upgrades and Downgrades

VRCA has been the subject of a number of analyst reports. Royal Bank of Canada downgraded shares of Verrica Pharmaceuticals from an “outperform” rating to a “sector perform” rating and lowered their price target for the company from $11.00 to $2.00 in a report on Tuesday. Brookline Capital Management reiterated a “hold” rating on shares of Verrica Pharmaceuticals in a report on Wednesday, October 2nd. TD Cowen decreased their price target on Verrica Pharmaceuticals from $15.00 to $10.00 and set a “buy” rating on the stock in a report on Monday, October 21st. Finally, Needham & Company LLC reaffirmed a “hold” rating on shares of Verrica Pharmaceuticals in a research note on Tuesday. Three investment analysts have rated the stock with a hold rating and three have issued a buy rating to the company’s stock. Based on data from MarketBeat, Verrica Pharmaceuticals currently has a consensus rating of “Moderate Buy” and an average price target of $9.60.

Verrica Pharmaceuticals Company Profile

Verrica Pharmaceuticals Inc, a clinical-stage dermatology therapeutics company, develops medications for the treatment of skin diseases in the United States. Its product pipeline comprises YCANTH (VP-102), which is in phase III clinical trial for the treatment of common warts; and has completed phase II clinical trial for the treatment of external genital warts.